Entrada Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Entrada Therapeutics Free Cash Flow (FCF) History (TRDA)
Entrada Therapeutics reported −$129.6M in free cash flow for fiscal 2025, a decrease of $84.8M from the previous fiscal year, with a free cash flow margin of −509.63%.
View full Entrada Therapeutics company overviewEntrada Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$129.6M | −$84.8M | — | −509.63% |
| 2024 | 2024-12-31 | −$44.7M | −$178.9M | — | −21.21% |
| 2023 | 2023-12-31 | $134.2M | $230.9M | — | +104.01% |
| 2022 | 2022-12-31 | −$96.7M | −$41.2M | — | — |
| 2021 | 2021-12-31 | −$55.4M | −$27.6M | — | — |
| 2020 | 2020-12-31 | −$27.9M | — | — | — |
Entrada Therapeutics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$32.5M | −$2.7M | — | −3616.26% |
| Q1 2026 | 2026-03-31 | −$41.7M | −$2.1M | — | −4770.17% |
| Q4 2025 | 2025-12-31 | −$32.4M | −$170,000 | — | −2495.00% |
| Q3 2025 | 2025-09-30 | −$28.5M | −$3.6M | — | −1764.81% |
| Q2 2025 | 2025-06-30 | −$29.8M | −$68.6M | — | −1526.36% |
| Q1 2025 | 2025-03-31 | −$39.7M | −$13.3M | — | −192.87% |
| Q4 2024 | 2024-12-31 | −$32.2M | −$27.3M | — | −86.21% |
| Q3 2024 | 2024-09-30 | −$24.9M | $1.0M | — | −127.26% |
| Q2 2024 | 2024-06-30 | $38.8M | $75.4M | — | +40.96% |
| Q1 2024 | 2024-03-31 | −$26.4M | −$228.1M | — | −44.58% |
| Q4 2023 | 2023-12-31 | −$5.0M | $23.0M | — | −11.92% |
| Q3 2023 | 2023-09-30 | −$25.9M | $2.4M | — | −59.31% |
| Q2 2023 | 2023-06-30 | −$36.6M | −$17.8M | — | −201.50% |
| Q1 2023 | 2023-03-31 | $201.7M | $223.3M | — | +798.62% |
| Q4 2022 | 2022-12-31 | −$28.0M | −$6.1M | — | — |
| Q3 2022 | 2022-09-30 | −$28.3M | −$13.4M | — | — |
| Q2 2022 | 2022-06-30 | −$18.8M | −$9.3M | — | — |
| Q1 2022 | 2022-03-31 | −$21.6M | −$12.3M | — | — |
| Q4 2021 | 2021-12-31 | −$21.9M | — | — | — |
| Q3 2021 | 2021-09-30 | −$14.9M | — | — | — |
| Q2 2021 | 2021-06-30 | −$9.5M | — | — | — |
| Q1 2021 | 2021-03-31 | −$9.2M | — | — | — |
Entrada Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$27.9M to −$129.6M, a net decrease of $101.7M. Entrada Therapeutics's latest reported quarter, Q2 2026, generated −$32.5M in free cash flow, a decrease of $2.7M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Entrada Therapeutics filings at SEC.gov ↗